2026-2032 Global Alzheimer's Blood Tests Industry Research & Trends Analysis Report- YH Research

Home > Reports >Medical Devices & Consumables > 2026-2032 Global Alzheimer's Blood Tests Industry Research & Trends Analysis Report

2026-2032 Global Alzheimer's Blood Tests Industry Research & Trends Analysis Report

Publication Date: 2026-07-05
Report Id: 3115154
Industry: Medical Devices & Consumables
Report Page: 136
Chart: 140

PDF Download

Publication Date: 2026-07-05
Report Id: 3115154
Industry: Medical Devices & Consumables
Report Page: 136
Chart: 140

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Alzheimer's Blood Tests
1.2 Global Alzheimer's Blood Tests Market Size and Forecast
1.3 China Alzheimer's Blood Tests Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Alzheimer's Blood Tests Share in Global Market, 2021-2032
1.4.2 Alzheimer's Blood Tests Market Size: China VS Global, 2021-2032
1.5 Alzheimer's Blood Tests Market Dynamics
1.5.1 Alzheimer's Blood Tests Market Drivers
1.5.2 Alzheimer's Blood Tests Market Restraints
1.5.3 Alzheimer's Blood Tests Industry Trends
1.5.4 Alzheimer's Blood Tests Industry Policy

2 Competitive Landscape by Company
2.1 Global Alzheimer's Blood Tests Revenue by Company, 2021-2026
2.2 Global Alzheimer's Blood Tests Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Alzheimer's Blood Tests Concentration Ratio
2.4 Global Alzheimer's Blood Tests Mergers & Acquisitions, Expansion Plans
2.5 Global Alzheimer's Blood Tests Manufacturers Product Type
2.6 Global Geographic Distribution of Alzheimer's Blood Tests Companies

3 China Competitive Situation by Company
3.1 China Alzheimer's Blood Tests Revenue by Company, 2021-2026
3.2 China Alzheimer's Blood Tests Alzheimer's Blood Tests Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Alzheimer's Blood Tests Market, Revenue Percentage of Local Players VS Foreign Players (2021-2032)

4 Industry Chain Analysis
4.1 Alzheimer's Blood Tests Industry Chain
4.2 Alzheimer's Blood Tests Upstream Analysis
4.3 Alzheimer's Blood Tests Midstream Analysis
4.4 Alzheimer's Blood Tests Downstream Analysis

5 Sights by Type
5.1 Alzheimer's Blood Tests Classification by Type
5.1.1 Chemiluminescence Immunoassay
5.1.2 Single-molecule and Other
5.1.3 Others
5.2 by Type, Global Alzheimer's Blood Tests Market Size & CAGR, 2021 VS 2025 VS 2032
5.3 by Type, Global Alzheimer's Blood Tests Market Size, 2021-2032

6 Sights by Testing Markers
6.1 Alzheimer's Blood Tests Classification by Testing Markers
6.1.1 Single Biomarker Tests
6.1.2 Multi-Biomarker Panel Tests
6.1.3 Others
6.2 by Testing Markers, Global Alzheimer's Blood Tests Market Size & CAGR, 2021 VS 2025 VS 2032
6.3 by Testing Markers, Global Alzheimer's Blood Tests Market Size, 2021-2032

7 Sights by Commercialization Status
7.1 Alzheimer's Blood Tests Classification by Commercialization Status
7.1.1 Commercialized Products
7.1.2 Products under Development or Registration
7.1.3 Research Use Only Products
7.2 by Commercialization Status, Global Alzheimer's Blood Tests Market Size & CAGR, 2021 VS 2025 VS 2032
7.3 by Commercialization Status, Global Alzheimer's Blood Tests Market Size, 2021-2032

8 Sights by Application
8.1 Alzheimer's Blood Tests Segment by Application
8.1.1 Clinical
8.1.2 Non-clinical
8.2 by Application, Global Alzheimer's Blood Tests Market Size & CAGR, 2021 VS 2025 VS 2032
8.3 by Application, Global Alzheimer's Blood Tests Market Size, 2021-2032

9 Sights by Region
9.1 By Region, Global Alzheimer's Blood Tests Market Size, 2021 VS 2025 VS 2032
9.2 By Region, Global Alzheimer's Blood Tests Market Size, 2021-2032
9.3 North America
9.3.1 North America Alzheimer's Blood Tests Market Size & Forecasts, 2021-2032
9.3.2 By Country, North America Alzheimer's Blood Tests Market Size Market Share
9.4 Europe
9.4.1 Europe Alzheimer's Blood Tests Market Size & Forecasts, 2021-2032
9.4.2 By Country, Europe Alzheimer's Blood Tests Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Alzheimer's Blood Tests Market Size & Forecasts, 2021-2032
9.5.2 By Country/Region, Asia Pacific Alzheimer's Blood Tests Market Size Market Share
9.6 South America
9.6.1 South America Alzheimer's Blood Tests Market Size & Forecasts, 2021-2032
9.6.2 By Country, South America Alzheimer's Blood Tests Market Size Market Share
9.7 Middle East & Africa

10 Sights by Country Level
10.1 By Country, Global Alzheimer's Blood Tests Market Size & CAGR，2021 VS 2025 VS 2032
10.2 By Country, Global Alzheimer's Blood Tests Market Size, 2021-2032
10.3 United States
10.3.1 United States Alzheimer's Blood Tests Market Size, 2021-2032
10.3.2 By Company, United States Alzheimer's Blood Tests Revenue Market Share, 2025
10.3.3 by Type, United States Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.3.4 by Application, United States Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.4 Europe
10.4.1 Europe Alzheimer's Blood Tests Market Size, 2021-2032
10.4.2 By Company, Europe Alzheimer's Blood Tests Revenue Market Share, 2025
10.4.3 by Type, Europe Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.4.4 by Application, Europe Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.5 China
10.5.1 China Alzheimer's Blood Tests Market Size, 2021-2032
10.5.2 By Company, China Alzheimer's Blood Tests Revenue Market Share, 2025
10.5.3 by Type, China Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.5.4 by Application, China Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.6 Japan
10.6.1 Japan Alzheimer's Blood Tests Market Size, 2021-2032
10.6.2 By Company, Japan Alzheimer's Blood Tests Revenue Market Share, 2025
10.6.3 by Type, Japan Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.6.4 by Application, Japan Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.7 South Korea
10.7.1 South Korea Alzheimer's Blood Tests Market Size, 2021-2032
10.7.2 By Company, South Korea Alzheimer's Blood Tests Revenue Market Share, 2025
10.7.3 by Type, South Korea Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.7.4 by Application, South Korea Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.8 Southeast Asia
10.8.1 Southeast Asia Alzheimer's Blood Tests Market Size, 2021-2032
10.8.2 By Company, Southeast Asia Alzheimer's Blood Tests Revenue Market Share, 2025
10.8.3 by Type, Southeast Asia Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.8.4 by Application, Southeast Asia Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.9 India
10.9.1 India Alzheimer's Blood Tests Market Size, 2021-2032
10.9.2 By Company, India Alzheimer's Blood Tests Revenue Market Share, 2025
10.9.3 by Type, India Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.9.4 by Application, India Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.10 Middle East & Africa
10.10.1 Middle East & Africa Alzheimer's Blood Tests Market Size, 2021-2032
10.10.2 By Company, Middle East & Africa Alzheimer's Blood Tests Revenue Market Share, 2025
10.10.3 by Type, Middle East & Africa Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032
10.10.4 by Application, Middle East & Africa Alzheimer's Blood Tests Revenue Market Share, 2025 VS 2032

11 Company Profile
11.1 Quanterix
11.1.1 Quanterix Company Information, Head Office, Market Area, and Industry Position
11.1.2 Quanterix Company Profile and Main Business
11.1.3 Quanterix Alzheimer's Blood Tests Models, Specifications, and Application
11.1.4 Quanterix Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.1.5 Quanterix Recent Developments
11.2 Sysmex
11.2.1 Sysmex Company Information, Head Office, Market Area, and Industry Position
11.2.2 Sysmex Company Profile and Main Business
11.2.3 Sysmex Alzheimer's Blood Tests Models, Specifications, and Application
11.2.4 Sysmex Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.2.5 Sysmex Recent Developments
11.3 Fujirebio
11.3.1 Fujirebio Company Information, Head Office, Market Area, and Industry Position
11.3.2 Fujirebio Company Profile and Main Business
11.3.3 Fujirebio Alzheimer's Blood Tests Models, Specifications, and Application
11.3.4 Fujirebio Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.3.5 Fujirebio Recent Developments
11.4 Vazyme
11.4.1 Vazyme Company Information, Head Office, Market Area, and Industry Position
11.4.2 Vazyme Company Profile and Main Business
11.4.3 Vazyme Alzheimer's Blood Tests Models, Specifications, and Application
11.4.4 Vazyme Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.4.5 Vazyme Recent Developments
11.5 Meso Scale Discovery
11.5.1 Meso Scale Discovery Company Information, Head Office, Market Area, and Industry Position
11.5.2 Meso Scale Discovery Company Profile and Main Business
11.5.3 Meso Scale Discovery Alzheimer's Blood Tests Models, Specifications, and Application
11.5.4 Meso Scale Discovery Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.5.5 Meso Scale Discovery Recent Developments
11.6 Alamar Biosciences
11.6.1 Alamar Biosciences Company Information, Head Office, Market Area, and Industry Position
11.6.2 Alamar Biosciences Company Profile and Main Business
11.6.3 Alamar Biosciences Alzheimer's Blood Tests Models, Specifications, and Application
11.6.4 Alamar Biosciences Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.6.5 Alamar Biosciences Recent Developments
11.7 Hoyotek
11.7.1 Hoyotek Company Information, Head Office, Market Area, and Industry Position
11.7.2 Hoyotek Company Profile and Main Business
11.7.3 Hoyotek Alzheimer's Blood Tests Models, Specifications, and Application
11.7.4 Hoyotek Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.7.5 Hoyotek Recent Developments
11.8 PeopleBio
11.8.1 PeopleBio Company Information, Head Office, Market Area, and Industry Position
11.8.2 PeopleBio Company Profile and Main Business
11.8.3 PeopleBio Alzheimer's Blood Tests Models, Specifications, and Application
11.8.4 PeopleBio Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.8.5 PeopleBio Recent Developments
11.9 Yonghe-sun
11.9.1 Yonghe-sun Company Information, Head Office, Market Area, and Industry Position
11.9.2 Yonghe-sun Company Profile and Main Business
11.9.3 Yonghe-sun Alzheimer's Blood Tests Models, Specifications, and Application
11.9.4 Yonghe-sun Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.9.5 Yonghe-sun Recent Developments
11.10 MagQu
11.10.1 MagQu Company Information, Head Office, Market Area, and Industry Position
11.10.2 MagQu Company Profile and Main Business
11.10.3 MagQu Alzheimer's Blood Tests Models, Specifications, and Application
11.10.4 MagQu Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.10.5 MagQu Recent Developments
11.11 Beckman Coulter Diagnostics
11.11.1 Beckman Coulter Diagnostics Company Information, Head Office, Market Area, and Industry Position
11.11.2 Beckman Coulter Diagnostics Company Profile and Main Business
11.11.3 Beckman Coulter Diagnostics Alzheimer's Blood Tests Models, Specifications, and Application
11.11.4 Beckman Coulter Diagnostics Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.11.5 Beckman Coulter Diagnostics Recent Developments
11.12 Lychix
11.12.1 Lychix Company Information, Head Office, Market Area, and Industry Position
11.12.2 Lychix Company Profile and Main Business
11.12.3 Lychix Alzheimer's Blood Tests Models, Specifications, and Application
11.12.4 Lychix Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.12.5 Lychix Recent Developments
11.13 Roche
11.13.1 Roche Company Information, Head Office, Market Area, and Industry Position
11.13.2 Roche Company Profile and Main Business
11.13.3 Roche Alzheimer's Blood Tests Models, Specifications, and Application
11.13.4 Roche Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.13.5 Roche Recent Developments
11.14 Shenzhen Anqun
11.14.1 Shenzhen Anqun Company Information, Head Office, Market Area, and Industry Position
11.14.2 Shenzhen Anqun Company Profile and Main Business
11.14.3 Shenzhen Anqun Alzheimer's Blood Tests Models, Specifications, and Application
11.14.4 Shenzhen Anqun Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.14.5 Shenzhen Anqun Recent Developments
11.15 Spear Bio
11.15.1 Spear Bio Company Information, Head Office, Market Area, and Industry Position
11.15.2 Spear Bio Company Profile and Main Business
11.15.3 Spear Bio Alzheimer's Blood Tests Models, Specifications, and Application
11.15.4 Spear Bio Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.15.5 Spear Bio Recent Developments
11.16 Suzhou Astrabio
11.16.1 Suzhou Astrabio Company Information, Head Office, Market Area, and Industry Position
11.16.2 Suzhou Astrabio Company Profile and Main Business
11.16.3 Suzhou Astrabio Alzheimer's Blood Tests Models, Specifications, and Application
11.16.4 Suzhou Astrabio Alzheimer's Blood Tests Revenue and Gross Margin, 2021-2026
11.16.5 Suzhou Astrabio Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Alzheimer's Blood Tests should grow from US$ 37.88 million in 2025 to US$ 275 million by 2032, with a CAGR of 29.2% for the period of 2026-2032.

Alzheimer's Blood Tests refer to blood-based assays used to assist in the evaluation of pathological changes associated with Alzheimer's disease. The core principle involves detecting neurodegenerative disease biomarkers—such as phosphorylated Tau proteins, β-amyloid-related ratios, GFAP, NfL, and others—in peripheral blood via venipuncture, in order to assess whether a patient may have amyloid deposition or Tau pathology related to Alzheimer's disease. The value of these tests lies in their greater convenience, lower invasiveness, cost advantages, and better accessibility compared to cerebrospinal fluid testing and PET imaging, making them suitable for early screening, adjunctive diagnosis, triage, and pre-treatment evaluation in patients with cognitive impairment. However, at present, they should generally not be interpreted as the sole basis for confirming a diagnosis of Alzheimer's disease; rather, clinical symptoms, cognitive assessments, neuroimaging findings, and other laboratory tests should be integrated for a comprehensive evaluation. It should be noted that the statistics reported in this report do not cover the overall end-market of the Alzheimer's disease blood testing industry, but rather the market for reagent products within it. The market size is calculated based on the product sales revenue of reagent manufacturers or brand owners, primarily covering clinically registered reagents, research-grade detection reagents, supporting calibrators, quality controls, and necessary consumables. Testing service fees charged to patients, pharmaceutical companies, or research projects by hospitals, third-party medical testing institutions, and central laboratories are not directly included in the market size reported herein. Adopting this statistical methodology serves, on the one hand, to avoid double-counting between reagent sales revenue and end-user testing service revenue, and on the other hand, to help harmonize revenue boundaries across different enterprises, thereby enabling more accurate comparisons of market share, technological approaches, and commercialization progress among various reagent manufacturers.

Alzheimer's Blood Tests

According to YH Research, the global market for Alzheimer's Blood Tests should grow from US$ 37.88 million in 2025 to US$ 275 million by 2032, with a CAGR of 29.2% for the period of 2026-2032.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

At this stage, market revenue primarily comes from registered reagents used in hospitals and clinical laboratories, research-grade detection reagents purchased by pharmaceutical companies and research institutions, and professional testing services provided by central laboratories. As the clinical value of blood-based biomarkers gradually gains recognition, the approval process for related products continues to advance, and disease-modifying therapies for Alzheimer's disease are progressively entering clinical practice, the use cases of Alzheimer's Blood Tests are extending from research procurement, drug development, and cohort studies to preliminary patient assessment, risk stratification, clinical triage, pre-treatment evaluation, and follow-up monitoring. It should be noted that blood tests currently remain an auxiliary assessment tool and cannot fully replace clinical symptom evaluation, cognitive assessment, neuroimaging, or other laboratory tests.

From a technological perspective, the market can be divided into chemiluminescence immunoassays, single-molecule and other ultra-sensitive immunoassays, as well as other methods such as immunochromatography, enzyme-linked immunosorbent assays, and immunomagnetic reduction. In the early stages of market development, the demand from research, drug development, cohort studies, and professional laboratory testing accounted for a relatively high proportion. Single-molecule and other ultra-sensitive platforms, with their ability to detect low-abundance biomarkers, occupied an important position in early commercialization. However, such platforms generally have high requirements for instrument performance, experimental conditions, operator expertise, and testing costs, making them unsuitable for large-scale deployment in routine hospitals and primary healthcare facilities in the short term. As product registration, clinical validation, and the introduction of automated platforms gradually advance, chemiluminescence immunoassays—leveraging their high throughput, favorable standardization levels, and compatibility with existing laboratory instrument systems—will capture more incremental clinical applications and gradually become the primary direction for scaled market development. Although other detection methods have certain limitations in sensitivity, specificity, or clinical acceptance, they still retain application spaces in research exploration, screening examinations, primary care, and price-sensitive markets due to their lower costs and flexible deployment. Their market share is expected to gradually decline but will not completely disappear. In terms of product segments, chemiluminescence immunoassays account for the largest share, representing 43.47% of the total market in 2025.

From the perspective of application scenarios, Alzheimer's Blood Tests products can be divided into two major categories—clinical applications and non-clinical applications—based on whether the test results directly enter the patient's diagnostic and treatment workflow. Clinical applications are primarily targeted at hospitals, memory clinics, neurology departments, clinical laboratories, and third-party medical testing institutions, and are used for early auxiliary assessment, triage, adjunctive diagnosis, differential diagnosis, pre-treatment evaluation, disease progression monitoring, and therapeutic effect observation in populations with cognitive impairment. Non-clinical applications mainly include drug development and clinical trials, research and cohort studies, as well as health management and population screening. Among these, drug development and clinical trials focus on subject prescreening, patient stratification, enrollment enrichment, efficacy evaluation, and longitudinal monitoring; research and cohort studies are primarily used for biomarker validation, disease mechanism research, natural history studies, and epidemiological investigations; health management and population screening can cover physical examination centers, community early screening, government public health projects, insurance health services, home-based sampling, and internet-based health management channels. Since testing channels, payment models, and delivery methods are not on the same classification dimension, care must be taken to avoid simple juxtaposition or double-counting when conducting market statistics. Currently, non-clinical applications account for the largest share, representing 75.61% of the total market in 2025.

There are notable differences in the development paths of different companies. Platform-based diagnostic companies such as Roche, Fujirebio, Sysmex, and Beckman Coulter primarily rely on their existing automated immunoassay instruments to gradually introduce blood-based biomarkers such as p-tau and Aβ into routine clinical testing workflows. Companies such as Quanterix, Meso Scale Discovery, Alamar Biosciences, and Spear Bio, on the other hand, have established technological advantages in single-molecule or other ultra-sensitive immunoassays, with their current revenue coming more from drug development, clinical trials, research projects, and professional laboratory testing needs. Companies such as PeopleBio and MagQu have adopted differentiated detection methods and have already achieved product commercialization in certain regional markets earlier. Given the significant differences in product maturity, regulatory approval status, and commercialization models across companies, market revenue statistics should be calculated separately for approved reagents, research-grade reagents, testing services, and cooperative development projects, rather than simply extrapolating revenue based on a company's overall business coverage or a single representative product.

The Chinese market for Alzheimer's Blood Tests reagents is still in the commercial introduction phase, but with growing clinical awareness, an increasing number of approved products, and the gradual refinement of testing pathways in hospital settings, the market size is expanding rapidly. Companies such as Hoyotek, Yonghe-sun, and Shenzhen Anqun entered the market relatively early, with some manufacturers having already obtained registration certificates for markers such as Aβ1-42 and p-tau181, and are progressively promoting product adoption in hospitals through their existing chemiluminescence, fluorescence immunochromatography, or digital ELISA platforms. Vazyme systematically established its presence in the Alzheimer's blood testing product space in 2024, achieving rapid volume growth through its relatively complete multi-marker product portfolio, core raw material development capabilities, and channel resources; however, as more companies enter the market, its share is expected to gradually return to a more reasonable level. Overall, the Chinese market will transition from being dominated by a few early players to a landscape of concurrent expansion among multiple manufacturers. After 2025, the number of new entrants has increased notably, and the combined revenue and market share of other domestic manufacturers will rise rapidly. At the same time, since some domestic products are still primarily focused on immunochromatography, screening-type tests, or regional projects, the standardization of hospital clinical pathways, product performance validation, departmental access, and reimbursement systems still need to be gradually improved. In the short term, the proportion of clinical applications should not be overestimated.

This report aims to provide a comprehensive study of the global market for Alzheimer's Blood Tests. Report Highlights:
(1) Global Alzheimer's Blood Tests market size (value), history data from 2021-2025, and forecast data from 2026 to 2032.

(2) Global Alzheimer's Blood Tests market competitive situation, revenue, and market share, from 2021 to 2025.

(3) China Alzheimer's Blood Tests market competitive situation, revenue, and market share, from 2021 to 2025.

(4) Global Alzheimer's Blood Tests segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Alzheimer's Blood Tests segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Alzheimer's Blood Tests industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
    Chemiluminescence Immunoassay
    Single-molecule and Other
    Others

Market segment by Testing Markers, covers
    Single Biomarker Tests
    Multi-Biomarker Panel Tests
    Others

Market segment by Commercialization Status, covers
    Commercialized Products
    Products under Development or Registration
    Research Use Only Products

Market segment by Application, can be divided into
    Clinical
    Non-clinical

Market segment by players, this report covers
    Quanterix
    Sysmex
    Fujirebio
    Vazyme
    Meso Scale Discovery
    Alamar Biosciences
    Hoyotek
    PeopleBio
    Yonghe-sun
    MagQu
    Beckman Coulter Diagnostics
    Lychix
    Roche
    Shenzhen Anqun
    Spear Bio
    Suzhou Astrabio